Needham & Company LLC appreciated $ 20.00 on Iterum Therapeutics (NASDAQ: ITRM) in a report issued on Wednesday morning. The company currently has a purchase price in the warehouse.
A number of other equity analysis analysts have also recently issued reports about the company. Zacks Investment Research downgraded Iterum Therapeutics from a grade to a sales rating in a research note on Friday, November 9th. Gabelli revised a purchase price of shares in Iterum Therapeutics in a research note on Monday, October 22. An investment analyst has rated the limited company with a holding rating and five have issued a purchase price to the company's share. The stock currently has a Consensus Rating on Buy and an average price target of $ 20.75.
Shares in the Iterum Therapeutics share traded at $ 0.11 during trading hours on Wednesday and amounted to $ 5.81. 11,530 shares in traded hands, compared to average volume of 12,187. Iterum Therapeutics has one year low at $ 5.31 and a year high of $ 13.00. The company has a debt ratio of 0.15, a quotient of 11.53 and a present value of 14.05.
Iterum Therapeutics (NASDAQ: ITRM) released last quarterly earnings results Wednesday, November 14th. The company reported ($ 1.24) earnings per share (EPS) for the quarter and struck Zack's consensus estimate of $ 1.97 by $ 0.73. The company had a turnover of $ 0.25 million for the quarter. On average, analysts analysts that Iterum Therapeutics will look for -10.82 EPS for the current year.
In related news, CEO Mark Chin acquired 58,000 shares of shares in a transaction dated 30 October. The shares were bought at an average cost of $ 6.10 per share, with a total value of $ 353,800. The acquisition was disclosed in a legal application with the SEC, which can be accessed via this link. In the last ninety days, insiders have bought 60,000 shares in the company's shares worth $ 374,020.
Hedge funds have recently bought and sold shares in the company. Frazier Management LLC bought a new position in Iterum Therapeutics in the 2nd quarter worth approximately $ 16,414,000. Granahan Investment Management Inc. MA bought a new stake in ITERUM Therapeutics shares in the second quarter worth approximately $ 2,570,000. Millennium Management LLC bought a new stake in Iterum Therapeutics shares in the second quarter worth approximately $ 1,867,000. Tiverton Asset Management LLC bought a new stake in Iterum Therapeutics shares in the second quarter worth approximately $ 1,529,000. Finally, Neuburgh Advisers LLC purchased a new stake in Iterum Therapeutics shares in the second quarter worth approximately $ 675,000. 47.63% of the share is currently owned by hedge funds and other institutional investors.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical stage pharmaceutical company, is committed to developing anti-infectious agents for resistant multi-drug pathogens in Ireland and the United States. The company develops sulopenem, a penem anti-infective compound with oral and IV formulations present in phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra-abdominal infections.
Additional reading: How to calculate the mutual value of a layer
Get news and ratings for Iterum Therapeutics Daily – Enter your email address below to get a brief daily summary of the latest news and analysts reviews for Iterum Therapeutics and related companies with MarketBeat.com's FREE Daily Newsletter.